Collectively, these data suggest that although these compounds do not inhibit acetylcholinesterase or monoamine oxidases to the same extent as current therapies available on the market, anthocyanins or their metabolites may have a safer profile as therapeutic agents, and thus could serve a complimentary purpose in enhancing current treatments for Alzheimer’s and Parkinson’s disease either through dietary intervention or as supplements [239,243,245]. This evidence concerns the gene ACHE and Parkinson disease.